Campbell IWPioglitazone - an oral antidiabetic agent and metabolic syndrome modulator. Can therapy translate into practice?Br J Diabetes Vasc Dis2005;5:209-16.
2.
McCallum RW, Fisher M.From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes . Br J Diabetes Vasc Dis2005;5:218-25.
3.
Charbonnel B. , Dormandy J., Erdmann E., Massi-Benedetti M., Skene A.The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care2004;27:1647-53.
4.
Staels B.PPARγ and atherosclerosis. Curr Med Res Opin2005;21(suppl 1):S13-S20.
5.
Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidaemia. Diabetes Care2005;28:1547-54.
6.
Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence and mortality in the elderly with diabetes. Diabetes Care2004;27:699-703.
7.
Belcher G., Lambert C., Goh KL et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J CLin Pract2004;58:833-7.
8.
Karter AJ, Ahmed AT, Liu J., Moffet HH, Parker MMPioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med2005;22:986-93.
